Udumyan R, Montgomery S, Fang F, et al. - Researchers used the largest general population-based cohort of patients with non–small cell lung cancer (NSCLC) to date, to determine if there exists a link between β-blocker use at the time of cancer diagnosis and lung cancer mortality. They utilized prospectively gathered data from the Swedish population and health registers in this retrospectively defined nationwide cohort investigation. Using the Swedish Cancer Register, they selected 18,429 patients who received a diagnosis of primary NSCLC between 2006 and 2014 and were observed until 2015. The deaths of 14,994 patients (including 13,398 from lung cancer) were reported during a median follow-up of 10.2 months. Findings revealed no link between β-blocker use and lung cancer mortality when evaluated in aggregate in the entire cohort, but proof for some β-blockers was less conclusive.